Juli M Bollinger1, Gail Geller2,3, Kevin Weinfurt4, Elizabeth May2, Stephanie R Morain5, Debra J H Mathews2,6, Jeremy Sugarman2,3. 1. Berman Institute of Bioethics, Johns Hopkins University, , Baltimore, MD, USA. jmurph46@jhu.edu. 2. Berman Institute of Bioethics, Johns Hopkins University, , Baltimore, MD, USA. 3. Department of Medicine, Johns Hopkins University School of Medicine, , Baltimore, MD, USA. 4. Department of Population Health Sciences, Duke University School of Medicine, , Durham, NC, USA. 5. Center for Medical Ethics and Health Policy, Baylor College of Medicine, , Houston, TX, USA. 6. Department of Pediatrics, Johns Hopkins University School of Medicine, , Baltimore, MD, USA.
Abstract
BACKGROUND: Pragmatic clinical trials (PCTs) are increasingly being conducted to efficiently generate evidence to inform healthcare decision-making. Despite their growing acceptance, PCTs may involve a variety of ethical issues, including the management of pragmatic clinical trial-collateral findings (PCT-CFs), that is, information that emerges in PCTs that is unrelated to the primary research questions but may have implications for patients, clinicians, and health systems. OBJECTIVE: We sought to understand patients' views about PCT-CF disclosure, including how, by whom, and the nature and extent of information provided. DESIGN: Prospective, qualitative focus group study. PARTICIPANTS: Focus groups were conducted in Baltimore, MD; Houston, TX; and Seattle, WA (overall N = 66), during July and August 2019. APPROACH: All groups discussed a hypothetical scenario involving the detection of a PCT-CF of contraindicated medications. Participants were asked about their reactions to the PCT-CF and issues related to its disclosure. KEY RESULTS: Reactions to learning about the PCT-CF were mixed, ranging from fear of a significant health problem, anger that the contraindicated medications had gone unnoticed and/or for being included in research without their permission, to gratitude for the information. Preferences for how such disclosures are made varied but were driven by several consistent desires, namely minimizing patient harm and anxiety and demonstrating trust and respect. Many wanted their treating clinician to be informed of the PCT-CF so that they would be prepared to answer patients' questions and to discuss treatment options. CONCLUSIONS: The detection of PCT-CFs is likely to increase with further expansion of PCTs. As such, clinicians will undoubtedly become involved in the management of PCT-CFs. Our data illustrate some of the challenges clinicians may face when their patients are informed of a PCT-CF and the need to develop guidance for disclosing PCT-CFs in ways that align with patients' preferences and values.
BACKGROUND: Pragmatic clinical trials (PCTs) are increasingly being conducted to efficiently generate evidence to inform healthcare decision-making. Despite their growing acceptance, PCTs may involve a variety of ethical issues, including the management of pragmatic clinical trial-collateral findings (PCT-CFs), that is, information that emerges in PCTs that is unrelated to the primary research questions but may have implications for patients, clinicians, and health systems. OBJECTIVE: We sought to understand patients' views about PCT-CF disclosure, including how, by whom, and the nature and extent of information provided. DESIGN: Prospective, qualitative focus group study. PARTICIPANTS: Focus groups were conducted in Baltimore, MD; Houston, TX; and Seattle, WA (overall N = 66), during July and August 2019. APPROACH: All groups discussed a hypothetical scenario involving the detection of a PCT-CF of contraindicated medications. Participants were asked about their reactions to the PCT-CF and issues related to its disclosure. KEY RESULTS: Reactions to learning about the PCT-CF were mixed, ranging from fear of a significant health problem, anger that the contraindicated medications had gone unnoticed and/or for being included in research without their permission, to gratitude for the information. Preferences for how such disclosures are made varied but were driven by several consistent desires, namely minimizing patient harm and anxiety and demonstrating trust and respect. Many wanted their treating clinician to be informed of the PCT-CF so that they would be prepared to answer patients' questions and to discuss treatment options. CONCLUSIONS: The detection of PCT-CFs is likely to increase with further expansion of PCTs. As such, clinicians will undoubtedly become involved in the management of PCT-CFs. Our data illustrate some of the challenges clinicians may face when their patients are informed of a PCT-CF and the need to develop guidance for disclosing PCT-CFs in ways that align with patients' preferences and values.
Authors: Carrie M Nielson; Amanda F Petrik; Lorie Jacob; William M Vollmer; Erin M Keast; Jennifer L Schneider; Jennifer S Rivelli; Tanya J Kapka; Richard T Meenan; Rajasekhara R Mummadi; Beverly B Green; Gloria D Coronado Journal: Cancer Med Date: 2018-08-13 Impact factor: 4.452
Authors: Joseph Ali; Stephanie R Morain; P Pearl O'Rourke; Benjamin Wilfond; Emily C O'Brien; Christina K Zigler; Karen L Staman; Kevin P Weinfurt; Jeremy Sugarman Journal: Contemp Clin Trials Date: 2022-01-05 Impact factor: 2.226
Authors: Kevin P Weinfurt; Juli M Bollinger; Elizabeth May; Gail Geller; Debra J H Mathews; Stephanie R Morain; Lorrie Schmid; Diane L Bloom; Jeremy Sugarman Journal: J Gen Intern Med Date: 2021-08-12 Impact factor: 6.473
Authors: Stephanie R Morain; Debra J H Mathews; Gail Geller; Juli Bollinger; Kevin Weinfurt; Jeffrey G Jarvik; Elizabeth May; Jeremy Sugarman Journal: Healthc (Amst) Date: 2021-09-29